Bicycle therapeutics to present data for zelenectide pevedotin at 2024 san antonio breast cancer symposium and provide program update

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer (tnbc) patients with nectin4 gene amplification at the 2024 san antonio breast cancer symposium (sabcs.
BCYC Ratings Summary
BCYC Quant Ranking